Matthew Call
2022
In 2022, Matthew Call earned a total compensation of $2.9M as Chief Operating Officer at iTeos Therapeutics, a 32% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $172,058 |
|---|---|
| Option Awards | $2,225,164 |
| Salary | $452,490 |
| Other | $14,000 |
| Total | $2,863,712 |
Call received $2.2M in option awards, accounting for 78% of the total pay in 2022.
Call also received $172.1K in non-equity incentive plan, $452.5K in salary and $14K in other compensation.
Rankings
In 2022, Matthew Call's compensation ranked 1,255th out of 5,506 executives tracked by ExecPay. In other words, Call earned more than 77.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,255 out of 5,506 | 77th |
Division Manufacturing | 614 out of 2,985 | 79th |
Major group Chemicals And Allied Products | 226 out of 1,340 | 83rd |
Industry group Drugs | 205 out of 1,243 | 84th |
Industry Biological Products, Except Diagnostic Substances | 51 out of 287 | 82nd |
Source: SEC filing on April 27, 2023.
Call's colleagues
We found two more compensation records of executives who worked with Matthew Call at iTeos Therapeutics in 2022.